2019冠状病毒病大流行期间卵巢癌的管理
Management of ovarian cancer during the COVID-19 pandemic.
作者信息
Mandato Vincenzo Dario, Aguzzoli Lorenzo
机构信息
Unit of Obstetrics and Gynecology, Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, Italy.
Unit of Surgical Gynecological Oncology, Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, Italy.
出版信息
Int J Gynaecol Obstet. 2020 Jun;149(3):382-383. doi: 10.1002/ijgo.13167. Epub 2020 Apr 29.
Abstract
A new strategy of avoiding ultra‐radical surgery and increasing neoadjuvant therapy for the treatment of ovarian cancer is required during the COVID‐19 pandemic.
摘要
在新冠疫情期间，需要一种新的策略来避免超根治性手术，并增加卵巢癌治疗的新辅助治疗。
相似文献
1
Management of ovarian cancer during the COVID-19 pandemic.2019冠状病毒病大流行期间卵巢癌的管理
Int J Gynaecol Obstet. 2020 Jun;149(3):382-383. doi: 10.1002/ijgo.13167. Epub 2020 Apr 29.
2
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.新辅助化疗与中间型减瘤术治疗晚期输卵管-卵巢癌：来自 EORTC 55971 和 CHORUS 试验的个体患者数据的汇总分析。
Lancet Oncol. 2018 Dec;19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. Epub 2018 Nov 6.
3
Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.新辅助化疗后延迟细胞减灭术治疗晚期上皮性卵巢癌的生存结局。
Int J Gynecol Cancer. 2020 Dec;30(12):1935-1942. doi: 10.1136/ijgc-2020-001658. Epub 2020 Oct 29.
4
Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.前瞻性手术与新辅助化疗后间隔减瘤手术治疗 IIIC 期和 IV 期卵巢癌患者的研究，SGOG SUNNY（SOC-2）试验方案。
J Gynecol Oncol. 2020 Sep;31(5):e86. doi: 10.3802/jgo.2020.31.e86.
5
The "collateral damage" of the war on COVID-19: impact of the pandemic on the care of epithelial ovarian cancer.抗击 COVID-19 战争的“附带损害”：大流行对上皮性卵巢癌治疗的影响。
Med Oncol. 2021 Sep 28;38(11):137. doi: 10.1007/s12032-021-01588-6.
6
Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer.接受或未接受新辅助化疗的晚期卵巢癌患者辅助性腹腔内化疗的临床获益及耐受性
World J Clin Oncol. 2019 May 24;10(5):201-212. doi: 10.5306/wjco.v10.i5.201.
7
Alternative management for gynecological cancer care during the COVID-2019 pandemic: A Latin American survey.2019年冠状病毒病大流行期间妇科癌症护理的替代管理：一项拉丁美洲调查。
Int J Gynaecol Obstet. 2020 Sep;150(3):368-378. doi: 10.1002/ijgo.13272. Epub 2020 Jul 17.
8
[Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].同步性结直肠癌肝转移患者新辅助化疗后肝手术与直接手术的预后比较研究
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Mar 25;24(3):248-255. doi: 10.3760/cma.j.cn.441530-20200606-00346.
9
Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer.老年女性卵巢癌初始治疗策略的比较效果。
Cancer. 2014 Apr 15;120(8):1246-54. doi: 10.1002/cncr.28508. Epub 2014 Jan 17.
10
Initial incomplete surgery modifies prognosis in advanced ovarian cancer regardless of subsequent management.初始手术不完整会改变晚期卵巢癌的预后，无论后续如何处理。
Anticancer Res. 2015 Apr;35(4):2315-20.
引用本文的文献
1
Impact of the COVID-19 pandemic on cancer recurrence rates in patients with ovarian cancer.2019年冠状病毒病大流行对卵巢癌患者癌症复发率的影响。
Gynecol Oncol Rep. 2025 May 6;59:101763. doi: 10.1016/j.gore.2025.101763. eCollection 2025 Jun.
2
Clinical Remission Rates in Patients With Epithelial Ovarian Cancer Before and After the Onset of the COVID 19 Pandemic in an Integrated Healthcare Delivery System.综合医疗服务体系中上皮性卵巢癌患者在新冠疫情爆发前后的临床缓解率
Cancer Manag Res. 2025 Feb 12;17:281-291. doi: 10.2147/CMAR.S487894. eCollection 2025.
3
Real-life treatment patterns and time to next treatment among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland Study.在 PARP 抑制剂时代之前，卵巢癌患者的真实治疗模式和下一次治疗时间：OCRWE-芬兰研究。
Acta Oncol. 2024 Oct 16;63:772-782. doi: 10.2340/1651-226X.2024.40325.
4
Management of Gynecologic Cancer During COVID-19 Pandemic: South Asian Perspective.COVID-19 大流行期间妇科癌症的管理：南亚视角。
Cancer Control. 2022 Jan-Dec;29:10732748221119349. doi: 10.1177/10732748221119349.
5
The Impact of the SARS-CoV-2 Pandemic on Healthcare Provision in Italy to non-COVID Patients: a Systematic Review.新冠疫情对意大利非新冠患者医疗服务的影响：一项系统综述
Mediterr J Hematol Infect Dis. 2022 Jan 1;14(1):e2022012. doi: 10.4084/mjhid.2022.012. eCollection 2022.
6
COVID-19 and its implications for obstetrics and gynecology practice in Africa.COVID-19 及其对非洲妇产科实践的影响。
Pan Afr Med J. 2021 Jan 7;38:15. doi: 10.11604/pamj.2021.38.15.25520. eCollection 2021.
7
Management of gynecological cancers in the COVID-19 era: a survey from Turkey.新冠疫情时代妇科癌症的管理：来自土耳其的一项调查。
J Turk Ger Gynecol Assoc. 2020 Dec 4;21(4):265-271. doi: 10.4274/jtgga.galenos.2020.2020.0071.
8
Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments.2019年冠状病毒病：从临床表现、发病机制到新型管理方法与治疗的简要综述
Front Oncol. 2020 Oct 29;10:572329. doi: 10.3389/fonc.2020.572329. eCollection 2020.
9
Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience.日本东京一家大型妇科肿瘤机构中COVID-19疫情的影响：单中心经验
J Ovarian Res. 2020 Sep 11;13(1):105. doi: 10.1186/s13048-020-00711-x.
10
A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic.新型冠状病毒肺炎大流行期间癌症护理临床实践指南及治疗建议综述
Cancers (Basel). 2020 Aug 29;12(9):2452. doi: 10.3390/cancers12092452.
本文引用的文献
1
Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal.在2019冠状病毒病大流行期间管理癌症护理：为实现共同目标而灵活应变与协作。
J Natl Compr Canc Netw. 2020 Mar 20:1-4. doi: 10.6004/jnccn.2020.7560.
2
Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis.新辅助化疗与初次肿瘤细胞减灭术治疗卵巢癌患者的疗效和安全性：一项荟萃分析。
J Gynecol Oncol. 2020 Mar;31(2):e12. doi: 10.3802/jgo.2020.31.e12. Epub 2019 Oct 21.
3
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.ESMO-ESGO 共识会议关于卵巢癌的建议：病理学和分子生物学，早期和晚期，交界性肿瘤和复发性疾病†。
Ann Oncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062.
4
Do critical care units play a role in the management of gynaecological oncology patients? The contribution of gynaecologic oncologist in running critical care units.重症监护病房在妇科肿瘤患者的管理中发挥作用吗？妇科肿瘤学家在管理重症监护病房中的贡献。
Eur J Cancer Care (Engl). 2017 Mar;26(2). doi: 10.1111/ecc.12438. Epub 2016 Jan 25.
Zotero 插件